L-TIL cells

L-TIL (Liquid Tumor-Infiltrating Lymphocytes) is an autologous adoptive cell therapy developed by Tianjin Medical University Cancer Institute and Hospital. Unlike traditional TIL therapies that require surgical resection of solid tumor tissue for lymphocyte extraction, L-TILs are derived from the patient's peripheral blood (liquid source). These lymphocytes are expanded ex vivo to generate a large population of tumor-reactive T cells, which are then re-infused into the patient. L-TIL is currently being evaluated in Phase II clinical trials as an adjuvant therapy for patients with resectable stage II to IIIB non-small cell lung cancer (NSCLC) who did not achieve a pathological complete response (pCR) following neoadjuvant treatment with immune checkpoint inhibitors and chemotherapy. In these trials, L-TIL is administered in combination with the PD-1 inhibitor tislelizumab to potentially eliminate residual micrometastatic disease and reduce the risk of recurrence.

Other names

Liquid Tumor-infiltrating LymphocytesAutologous peripheral blood TILs